Severe acute pancreatitis: clinical findings and therapeutic tools in Internal Medicine practice

BACKGROUND Recent advances in pathophysiology and therapeutic measures suggest that patients suffering from acute pancreatitis (AP) should undergo an early evaluation and treatment in Internal Medicine wards. Severe AP, usually associated with pancreatic necrosis and peripancreatic fluid collections, may be frequently complicated by distant organ(s) involvement. RESULTS The dreadful multi-organ failure may occur as an early event (during the first week of the disease) or in association with the infection of pancreatic necrosis in a later stage. So, during the clinical outcome, physicians may be compelled to counteract cardio-circulatory, pulmonary, renal, hepatic, haematological and hydro-electrolytic complex derangements. Arterial hypotension and shock may be consequence of hypovolemia and/or hearth failure or septic shock syndrome. Pleural effusions are frequent in the early phase of the disease as well as pulmonary densifications and renal insufficiency. Urinary, pulmonary, and biliary infections may intervene during all phases of the disease whereas pancreatic necrosis and fluid collections infections are more frequent after the second week of hospitalization. Prognostic evaluation should be obtained by simple and precise scoring system such as the modified Marshall score and CT-scan severity index. CONCLUSIONS Treatment must be initiated as soon as possible with special focusing on fluid and nutritional supplementation, pain control, cardio-respiratory support, antiproteases and antibiotics. Invasive procedures such as endoscopic sphincterotomy in biliary AP with cholangitis and/or obstruction and percutaneous drainage should be utilized in specific cases. Surgical necrosectomy is mandatory in patients with documented infection of pancreatic necrosis

Chronic asymptomatic hyperamylasemia unrelated to pancreatic disease

BACKGROUND Almost all patients presenting with chronic hyperamylasemia undergo an expensive, long, difficult and often repeated diagnostic workup even if this occurrence is not associated with symptoms or with known pancreatotoxic factors. This is in relationship with the poor knowledge that, beside hyperenzymemia secondary to pancreatic diseases and systemic illnesses, various non-pathological forms of chronic hyperamylasemia can occur in clinical practice. AIM OF THE STUDY This study was addressed to assess the clinical characteristics of patients presenting with chronic hyperamylasemia unrelated to pancreatic diseases (CHUPD). PATIENTS AND METHODS Data of all patients with CHUPD were retrospectively reviewed (June 1997-March 2007). Forty patients were included in the study; median follow- up was 33 months (range 3-84 months). CHUPD was secondary to: a) chronic benign pancreatic hyperamylasemia, 16 patients (40%); b) macroamylasemia, 15 patients (37.5%); c) salivary hyperamylasemia, 9 patients (22.5%). Gilbert’s syndrome was present in 13 patients (32.5%; 8 with macroamylasemia) and hyperdyslipidemia in 8 patients (20%; 5 with chronic benign pancreatic hyperamylasemia). Diagnostic exams (all in the normal range) performed before our observation were: Ca19-9 serum level in 37/40 (92.5%), ultrasonography and computed tomography-scan in all patients, endoscopic retrograde cholangiopancreatography in 21/40 (52.5%), abdominal magnetic resonance in 14/40 (35%). Previous diagnosis in these asymptomatic subjects were: chronic pancreatitis in 26 cases (65%); recurrent pancreatitis in 10 cases (25%); the remaining 4 patients (10%) were addressed without a specific diagnosis. CONCLUSIONS In clinical practice, the occurrence of an unexplained chronic hyperamylasemia very often allows to an unappropriate diagnostic workup due to the poor familiarity with CHUPD conditions